Search Medical Condition
Please enter condition
Please choose location

Esophageal Cancer Clinical Trials

A listing of Esophageal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (104) clinical trials

Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

60 patients of esophageal cancer with TNM stage of tumor stage II-III,who had received surgery and kept their tumor tissue, will be randomly divided into group A (receive cancer tissue antigen sensitized D-CIK immune cells in combination with chemotherapy treatment) or group B (just receive chemotherapy), and the randomize ratio ...

Phase

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab. This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and ...

Phase

Study of CGX1321 in Subjects With Advanced Solid Tumors

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced solid tumors including GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment who ...

Phase

Study of Apatinib in Metastatic Esophageal Cancer

Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.

Phase

Combination Margetuximab and Pembrolizumab for Advanced Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will evaluate safety of escalating doses of the combination treatment. The Dose Expansion ...

Phase

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib) A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor In Asian Participants With Advanced Non-Small-Cell Lung Cancer Urothelial Cancer Esophageal Cancer Or Cholangiocarcinoma

This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esophageal cancer and cholangiocarcinoma.

Phase

Genetic Predictors of Benefit to Pembrolizumab

The adaptive immune response mechanism can be co-opted by tumor cells leading to immune resistance and tumor growth. Recent success of anti-PD-1 antibodies (anti-PD-1) across a broad range of tumors suggests that this immune resistance can be reversed. Although responses have been observed to anti-PD-1, it is a subset of ...

Phase